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Background: Thyroid nodules are very common in general population. Even if benign, they may require a 
treatment in case of symptoms or cosmetic concerns. In the last years, minimally invasive treatments alternative 
to surgery have been developed, in particular ultrasound (US) guided radiofrequency ablation (RFA).
Methods: Twenty-four patients (9 males; 15 females; mean age 57.9 years) were treated and divided 
in two groups (A and B) according to the RFA needle used (18 gauge needle, AMICA; 17 gauge needle, 
COVIDIEN). Nodules and patients characteristics, together with procedural data were registered pre-
treatment and at 1-month follow-up. US visibility of the needle, volume of the nodules, symptoms and 
cosmetic concerns, complications were registered.
Results: Visibility of the needle was not significantly different in the two groups (P=0.0787). At 1 month 
the mean volume of the nodules dropped from 37.1 to 25 mL in group A and from 23.2 to 15.4 mL in group 
B; shrinkage rate (36.9% and 39.5%, respectively) was not significantly different (P=0.3137). Symptoms 
decreased from 3.1 to 1.4 in group A and from 4 to 1.6 in group B: no significant differences in reductions 
were observed (P=0.3305). Cosmetic score decreased from 3.7 to 3.4 in group A and from 3.9 to 3.6 in group 
B: no significant differences in reductions were observed (P=0.96). Total complication rate (18.2% in group 
A vs. 23.1% in group B) did not showed significant differences (P=0.5049). 
Conclusions: The two systems used in our study resulted equivalent in terms of US needle visibility, 
efficacy, symptom/cosmetic relief, safety. More patients and a longer follow-up are necessary to confirm our 
results.
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Introduction
Thyroid nodules are a common finding in general population. 
They can be approximatively discovered in 20–76% by 
ultrasound (US) scan, and in 3–7% by palpation (1).
Most nodules are asymptomatic and benign, and can 
be managed by observation only. However, even benign 
nodules may cause problems, such as subjective symptoms 
or cosmetic concerns (2).
Surgery and radioiodine therapy are still considered 
the mainstay of treatment, but both of these options have 
drawbacks. In particular, surgery carries a 2–10% complication 
rate and requires general anesthesia and hospitalization. 
Furthermore, it is costly, and may cause problems such as scar 
formation and iatrogenic hypothyroidism (3).
In recent years, nonsurgical minimally invasive 
techniques have been developed: percutaneous ethanol 
injection (PEI), laser ablation (LA), radiofrequency ablation 
(RFA), microwave ablation (MWA) and high-intensity 
focused ultrasound (HIFU) (4-8).
In particular, RFA is a minimally invasive treatment that 
had been used for benign and malignant tumors in liver, 
kidney and lung, resulting in long-term tissue necrosis (9-11).
Since 2006, many studies have evaluated feasibility, 
safety and efficacy of RFA in benign thyroid nodules, 
reporting good results in reducing both the volume of 
the nodules and the associated compressive symptoms/
cosmetic concerns. More recent studies have demonstrated 
the absence of regrowth at the mid-term follow-up controls 
(39.4±21.7 months) in 76% of cases (12).
In 2015, a strong consensus regarding RFA treatment of 
selected types of thyroid nodules was reached, and stated that 
this treatment should be applied to “large (volume >20 mL), 
nonfunctioning, benign thyroid nodules in patients 
presenting with local symptoms or cosmetic complaints 
when surgery is contraindicated or declined”. 
Nevertheless, only partial agreement has been reached 
for smaller (volume <20 mL) nonfunctioning, benign 
thyroid nodules that cause early local discomfort and show 
a significant growth over time (13).
In the present study, we report our experience and our 
preliminary results about RFA of benign thyroid nodules 
performed with two different devices, comparing our 
results.
Methods
This study was approved by our Internal Review Board. 
From June 2015 to June 2017 a total of 27 nodules in 24 
patients were treated (9 males; 15 females; mean age 57.9 
years; range, 34–83 years). In three patients two different 
nodules were treated in the same session, because the 
second nodule was closer to the main one and both could be 
reached by a single percutaneous access. In order to avoid 
the bias caused by the influence of the treatment of one 
nodule on the other one, in our results we considered the 
two contiguous nodules as a single entity.
Patients were divided in two groups, according to the 
system used: 
 Group A: monopolar, straight-type, internally 
cooled 18 gauge needle, with 7–10 mm active tip; 
AMICA, HS Hospital Service, Aprilia, Italy: from 
June 2015 to September 2016;
 Group B: monopolar, straight-type, internally 
cooled 17 gauge needle, with 7–10–20 mm active 
tip; COVIDIEN, Mansfield, MA, USA: from 
October 2016 to June 2017. 
Equipment
Arietta V70 (Hitachi Aloka Medical, Tokyo, Japan) was 
used as US-guidance during the procedure, for the initial 
diagnostic evaluation and for the follow-up. 
All patients were studied with US before the treatment 
by one of the two radiologists enrolled in the study, with 25 
and 22 years of thyroid US experience, respectively. The 
procedure was successively performed by one of them. 
Pre-ablation assessment 
Clinical history, symptoms and thyroid-focused laboratory 
data were registered for each patient. In particular, the 
symptom and cosmetic scores were evaluated as described in 
a previous consensus statement (14): all patients were asked 
to rate pressure symptoms on a 10 cm (grade 0–10) visual 
analogue scale (VAS) at enrollment and during follow-
up. The cosmetic score was evaluated by the clinician as 
follows: (I) no palpable mass; (II) no cosmetic problem but 
palpable mass; (III) a cosmetic problem on swallowing only; 
(IV) easily visible mass. 
The following nodules characteristics were assessed for 
each patient:
Number: 
 Single nodule;
 Dominant nodule in goiter.
Composition: 
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 Solid: solid portion >80%;
 Cystic: cystic portion >80%;
 Mixed: not meeting the criteria for solid or cystic.
Vascularization:
 0: spotty perinodular vascularization;
 1: perinodular vascularization with few intranodular 
vascular spots;
 2: both perinodular and intra-nodular vascularization.
Size:
 Volume: calculated through the formula V = 
πabc/6 (where V is the volume, a is the largest 
dimeter, b and c the two perpendicular diameters). 
Blinded results, in particular the average of the two 
measurements, were calculated before, during and 
after the procedure.
A US-guided fine needle aspiration cytology (FNAC) 
was performed within 36 months before the RFA to confirm 
the benignity of the nodules. Fiber laryngoscopy was not 
considered as a mandatory pre-ablation examination.
Inclusion criteria
 Symptomatic nodules (symptom score from 2 to 10): 
compressive symptoms, neck discomfort, foreign body 
sensation, throat irritation, dyspnea;
 Asymptomatic nodules (symptom score from 0 to 1) 
with:
 Tracheal deviation/compression;
 And/or enlargement >20% of the volume in the 
last year.
 Refusal or contraindications to surgery. 
Cosmetic concerns alone were not considered an inclusion 
criterion because of the lack of refund from our National 
Health Service (15). 
Exclusion criteria
 Nodules different from “Tir-1c” or “Tir-2” according 
to SIAPEC classification (16);
 Absence of a dominant thyroid nodule at US;
 Coagulation disorders.
Procedure
The following intraprocedural data were recorded for each 
patient: thin needle aspiration pre-RFA, number of skin 
punctures, active tip used, needle visibility, power output, 
total ablation time. All the procedures were performed on 
an outpatient basis. 
Laboratory tests, including complete blood count and 
blood coagulation tests (prothrombin time, activated partial 
thromboplastin time) were performed and the values were 
within normal range in all patients. Informed consent was 
obtained from each patient. 
The patients were put in a supine position with 
hyperextended neck. Two ground pads were positioned on 
the patient’s thighs before the procedure.
Sedation was obtained in accordance with the confidence 
of the interventional radiologist about the use of sedation 
drugs. We used a bland systemic sedoanalgesia (20 mg 
of sublingual morphin sulfate and 1–2 mg intravenous 
midazolam) together with local anesthesia (10–20 mg/mL 
of lidocaine hydrochloride) of the subcutaneous tissues. In 
the last five patients treated we also injected a mixture of 
anesthetics and physiological saline (mepivacaine 10 mL + 
bupivacaine 10 mL + physiological saline 10 mL) into the 
thyroid capsule, thus creating a “liquid isolating region”, in 
order to protect the surrounding structures from thermal 
injury and to reduce intra-procedural pain.
For mixed or mainly cystic nodules, fluid was aspirated 
under US-guidance with a 22 gauge needle just before 
ablation. 
The US visibility of the needle was judged by the 
operator and ranked on a scale from 1 to 4 (1: insufficient; 2: 
sufficient; 3: good; 4: excellent) (Figure 1).
The needle was positioned under US-guidance through 
a <2 mm incision of the anterior neck tissues. The incision 
was made in a central position of the nodule along the 
cranio-caudal axis in order to reach all of its parts with a 
single access, if possible. 
In all cases a trans-isthmic approach together with the 
“moving-shot” technique was used (2). This technique allows 
Figure 1 US-guided placement of the needle inside the nodule. 
Note the perfect US visibility (grade 4).
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creating multiple units of ablation of the nodule. The tip of 
the functioning needle is positioned into a specific nodule unit, 
until a growth in the electric impedance on the RF generator 
is recorded. When this happens, and usually corresponds to 
the moment when the typical US hyperechoic changes in the 
treated area appear, the needle is placed into the next unit to 
treat. The procedure is stopped when the entire area of the 
nodule becomes a transient hyperechoic zone.
In Figures 2-4 a scheme of our treatment modality is 
reported, “from riskier to safer”, in order to reduce the 
risk of double skin punctures and the risk of suboptimal 
visualization of the needle during RFA, especially in the 
most dangerous regions to treat.
After the procedure only cold ice was applied at the 
entry site. No neck compression was used. The patient was 
observed for 3–5 hours before discharge.
Post-ablation assessment
Our study protocol plans to perform a clinical and US 
evaluation at 1-, 3-, 6- and 12-month. However, all the 
results were evaluated only at 1 month follow-up as it was the 
only one post-ablation control reached by all the patients. 
At the 1 month follow-up the complications occurred, 
changes in volume of the treated nodules and any variation 
in the symptom and cosmetic score were registered. 
Complications were classified according to Common 
Terminology Criteria for Adverse Events (17). Safety 
was evaluated on the basis of the complications recorded 
immediately after the procedure and during the follow-up (18). 
Major complications were defined as complications that, if 
untreated, might threaten the patient’s life, lead to substantial 
morbidity and disability, or result in hospital admission or 
substantially lengthen the patient’s hospital stay (19-20). 
Minor complications included typical post-ablation syndrome 
(fever <38 ℃, pain, nausea and vomiting) if present for more 
than 4 days after the ablation procedure. The post-ablation 
syndrome lasting less than 4 days without any treatment is 
Figure 2 First, the nodule is visualized in its cranio-caudal 
development, to find its central point in this axis, where the skin 
will be punctured. Then, according to its dimensions, we divide 
the nodule in two or more regions in the cranio-caudal axis, first 
treating the more caudal region (for its location the most difficult 
to reach, especially in case of mediastinal development), then going 
to the more cranial regions (courtesy of Covidien).
Figure 3 Now we rotate the US probe in the transverse plane, and 
for each region we start to treat the areas nearest to the trachea. 
In this way, we treat without significant artifacts the area nearest 
to the “danger triangle”, which includes esophagus and recurrent 
laryngeal nerve (courtesy of Covidien).
Figure 4 Then, we go to the more lateral areas of the nodule, 
safer to treat respect to the regions near to the “danger triangle” 
(courtesy of Covidien).
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considered a side effect.
The volume of the nodules, symptom score and cosmetic 
score were evaluated as described in the pre-procedural 
assessment.
Statistical analysis
All calculations have been performed in R (R Foundation 
for Statistical Computing, Vienna, Austria). To evaluate the 
difference between the two needles in terms of efficacy, we 
used a linear model with the initial volume of the nodule 
and the assigned group (A or B) as predictors. We modeled 
the difference between the two groups as an interaction 
term. This was used to test whether the slopes in the two 
groups were significantly different. For all clinical scores, we 
performed a Mann-Whitney test on the differences between 
pre and post treatment for the two groups. To assess whether 
an increased risk of complications could arise in one of the 
two groups, we performed a logistic regression. Differences 
were considered significant when P<0.05.
Results
The characteristics of the nodules of the two groups are 
shown in the Tables 1,2. All the results reported were 
obtained at 1-month follow-up. 
Group A includes 11 patients (male:female ratio 5:6; 
mean age: 56.9 years; range, 44–75 years). In two patients 
two contiguous nodules were treated in the same procedure, 
therefore a total of 13 nodules were treated in the group A.
Group B includes 13 patients (male:female ratio 4:9; 
mean age: 58.7 years; range, 34–83 years). In one patient 
two contiguous nodules were treated in the same procedure, 
therefore a total of 14 nodules were treated in the group B.
Pre-ablation assessment
All the data collected before the treatments are more 
extensively reported in Tables 1-6.
Symptom score and cosmetic score
Group A
Eight patients (72.3%) complained of symptomatic nodules 
(from grade 2 to grade 8). The other three patients (27.7%) 
had asymptomatic nodules. Before the treatment, the mean 
symptom score in group A was 3.1.
Ten patients (90.9%) suffered from visible nodules (grade 
3–4 in cosmetic score), while the left one (9.1%) had a grade 
1 nodule. Before the treatment, the mean cosmetic score in 
Table 1 Nodule characteristics in group A
Patient Nodule Number Composition Vascularization US needle visibility
1 1 Single Solid 1 2
2 2 Goiter Cystic 1 4
3 3 Goiter Solid 2 2
4 4 Goiter Solid 2 4
5 5 Goiter Solid 2 3
6 6 Goiter Solid 2 3
6 7 Goiter Solid 1 3
7 8 Goiter Mixed 1 4
8 9 Goiter Solid 0 3
8 10 Goiter Solid 1 3
9 11 Goiter Solid 1 3
10 12 Goiter Mixed 1 2
11 13 Goiter Solid 1 1
Mean – – – 1.23 2.84
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Table 2 Nodules characteristics in group B
Patient Nodule Number Composition Vascularization US needle visibility
1 1 Goiter Solid 1 4
2 2 Goiter Solid 1 3
3 3 Goiter Solid 0 4
4 4 Goiter Mixed 0 4
5 5 Goiter Solid 0 3
6 6 Goiter Solid 2 4
7 7 Goiter Solid 1 3
8 8 Goiter Solid 1 2
8 9 Goiter Solid 1 2
9 10 Goiter Solid 1 3
10 11 Goiter Solid 1 3
11 12 Single Solid 1 3
12 13 Goiter Solid 1 4
13 14 Goiter Solid 0 4
Mean – – – 0.79 3.29
Table 3 Nodule volumes pre and post-treatment with % reduction 
in group A
Patient
Volume pre-
treatment (mL)
Volume at 1 
month (mL)
Reduction at 1 
month (%)
1 100.8 82.9 17.7
2 12.8 54.0 57.8
3 54.9 43.8 20.2
4 21.1 9.4 55.4
5 31.2 19.1 38.8
6 7.2 5.2 27.8
7 21.8 15.1 30.7
8 46.8 30.0 35.9
9 41.0 24.7 39.8
10 42.6 17.2 59.6
11 28.4 22.1 22.2
Mean 37.1 25 36.9
Table 4 Nodule volumes pre- and post-treatment with % reduction 
in group B
Patient
Volume pre-
treatment (mL)
Volume at 1 
month (mL)
Reduction at 1 
month (%)
1 35.3 18.4 47.9
2 17 11.2 34.1
3 6.6 2.4 66.7
4 9.1 4.9 46.2
5 9.7 4.6 52.6
6 52.0 35.6 31.5
7 20.3 15.4 24.1
8 48.1 32.3 32.8
9 20.3 13.3 34.5
10 25.2 12.9 48.8
11 48.2 42.2 12.4
12 7.7 5.8 24.7
13 2.1 0.9 57.1
Mean 23.2 15.4 39.5
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group A was 3.7. 
Group B
Eleven patients (84.6%) complained of symptomatic 
nodules. The other two patients (15.4%) had asymptomatic 
nodules. Before the treatment, the mean symptom score in 
group B was 4. 
All the patients (100%) suffered from visible nodules 
(grades 3–4 in cosmetic score). Before the treatment, the 
mean cosmetic score in group B was 3.9. 
Table 5 Symptom score and cosmetic score before treatment and at 1 month in group A. The mark (+) or (–) are present in the “cosmetic score at 
1 month evaluation” if the differences at follow-up are present but not sufficient to induce a change in the patient’s score
Patient Symptom score pre-treatment Symptom score at 1 month Cosmetic score pre-treatment Cosmetic score at 1 month
1 0 0 4 4
2 3 2 4 3
3 2 1 4 4
4 3 1 4 2
5 4 0 4 4 (–)
6 8 3 1 1
7 3 2 4 4 (–)
8 0 0 4 4
9 3 2 4 4 (–)
10 0 0 4 4 (–)
11 8 4 4 4
Mean 3.1 1.4 3.7 3.4
Table 6 Symptom score and cosmetic score before treatment and at 1 month in group B. The mark (+) or (–) are present in the “cosmetic score at 
1 month evaluation” if the differences at follow-up are present but not sufficient to induce a change in the patient’s score
Patient Symptom score pre-treatment Symptom score at 1 month Cosmetic score pre-treatment Cosmetic score at 1 month
1 5 3 4 4 (–)
2 2 1 4 4
3 6 2 4 4
4 4 2 4 4 (–)
5 3 2 4 4 (–)
6 5 2 4 4
7 7 2 4 4 (–)
8 6 3 4 4
9 0 0 4 4 (–)
10 3 0 4 4 (–)
11 6 2 4 4 (–)
12 5 2 3 1
13 0 0 4 2
Mean 4 1.6 3.9 3.6
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Nodules characteristics
Group A
Twelve out of 13 (92.3%) nodules were part of a goiter. 
Composition was mainly solid (76.9%), with 2 mixed 
(15.4%) and 1 cystic (7.7%) nodules.
Vascularization was principally intermediate (61.5%), the 
other cases being high (30.8%) or low (7.7%).
The mean volume of the nodules treated at baseline was 
37.1 mL (range, 7.2–100.8 mL).
Group B 
Thirteen out of 14 (92.9%) nodules were part of a goiter. 
Composition was mainly solid (92.9%), with only 1 
mixed nodule (7.1%).
Vascularization was principally intermediate (64.3%), the 
other cases being high (7.1%) or low (28.6%).
The mean volume of the nodules treated at baseline was 
23.2 mL (range, 2.1–52 mL).
Volume variation
Nodule volume at baseline did not significantly differ 
between the two groups (P=0.129).
Procedure
All the intraprocedural data are more extensively reported 
in Table 7. 
Group A
Five patients (45.5%) received a double skin puncture due 
to the dimensions of the nodule.
Mean ablation time was 10.1 minutes. Mean power 
output was 38.2 Watts.
The 10 mm active tip was used in nine patients (72.7%); 
7 mm active tip in the remaining three patients (27.3%).
Pre-procedural thin needle aspiration was performed in 
three patients (27.3%).
Group B
Three patients (23.1%) received a double skin puncture due 
to the dimensions of the nodule.
Mean ablation time was 10.8 minutes. Mean power 
output was 48.1 Watts.
The 10 mm active tip was used in eight patients (61.5%); 
7 mm active tip was used in three patients (23.1%); 20 mm 
active tip in the remaining two patients (15.4%).
All the nodules were mainly solid, therefore pre-procedural 
needle aspiration was never performed. 
Visibility
Mean US visibility of the needle during RFA corresponded 
to 2.84 in group A and to 3.29 in group B: no significant 
difference in visibility was observed by comparing the two 
needles (P=0.1448).
US changes
Group A
At 1 month follow-up the mean volume of the nodules 
treated was 25 mL (range, 5.2–82.9 mL). Comparing to 
the volume before the procedure, nodules of the group 
A showed a 36.9% mean volume reduction (range, 17.7–
59.6%). The volume significantly decreased compared to 
baseline (P<0.0001).
Group B
At 1 month follow-up the mean volume of the nodules 
treated was 15.4 mL (range, 0.9–42.2 mL). Comparing to 
the volume before the procedure, nodules of the group 
B showed a 39.5% mean volume reduction (range, 12.4–
66.7%) (Figures 5,6). The volume significantly decreased 
compared to baseline (P<0.0001). 
However, the slope of the linear regression line did not 
significantly differ between the two groups (P=0.3137; 
Table 7 Intraprocedural data divided by groups
Groups Double skin puncture (%)
Mean ablation time in 
minutes with (range)
Mean power in Watts with 
[range]
Needle aspiration pre-RFA 
(%)
Group A 5/11 (45.5) 10.1 (4.25–20.0) 38.2 [30–60] 3/11 (27.3)
Group B 3/13 (23.1) 10.8 (1.30–20.0) 48.1 [38–60] 0/13 (0)
Total 8/24 (33.3) 10.5 (1.30–20.0) 43.6 [30–60] 3/24 (12.5)
RFA, guided radiofrequency ablation.
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Figure 7). 
Clinical changes
No significant differences were observed by comparing the 
reduction of the symptom score and the cosmetic score 
between the two groups (Table 8).
Group A
An improvement in the symptom score was observed in all 
the symptomatic patients (8/11: 72.3%). In group A, the 
mean symptom score decreased from 3.1 to 1.4. None of 
the scores was found to be higher than 4 (Table 5).
A reduction of the cosmetic score in patients with a 
visible nodule (10/11: 90.9%) was observed in the 30% of 
Figure 6 Nodule volume at 1 month follow-up: 39 mm × 28 mm × 25 mm =14.4 mL. The nodule shows a 42.9% reduction from baseline. 
Note the hypoechoic changes of the ablated area.
Figure 5 Baseline volume of a solid thyroid nodule of the group B: 48 mm × 35 mm × 30 mm =25.2 mL.
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cases; 40% kept on being assigned to grade 4 even if their 
nodule was less evident; 30% did not showed any kind of 
changes at inspection (Table 5).
Group B
An improvement in the symptom score was observed in all 
the symptomatic patients (11/13: 84.6%). In group B, the 
mean symptom score decreased from 4 to 1.6. None of the 
scores was found to be higher than 3 (Table 6).
A reduction of the cosmetic score in patients with a 
visible nodule (all the patients with 3 or 4 grade symptom 
score before the treatment) was observed in 15.4% of cases; 
53.8% kept on being assigned grade 4 even if their nodule 
was less evident; 30.8% did not showed any kind of changes 
at inspection (Table 6). 
Complications
All the complications, divided in major and minor 
complications, are reported in the Tables 9,10.
Group A
One major complication (9.1%) was observed and consisted 
in recurrent laryngeal nerve palsy. The patient complained 
of voice change and dyspnea the day after the procedure. 
Fiberoptic bronchoscopy revealed a previously unknown 
condition of tracheomalacia. Steroid therapy was started 
immediately and led to resolution of the dyspnea in about 
24 hours; dysphonia resolved within 1 month. 
One minor complication (9.1%) was registered: a 3-mm 
thickness subcapsular hematoma, resolved itself without any 
treatment. 
Among the side effects, we observed one case of low-grade 
fever (<38 ℃) the day after the procedure in the context of a 
mild post-ablation syndrome, that resolved within 24 hours.
Group B
No major complications were observed.
Three minor complications were registered (23.1%), 
with two of them being related to pain during ablation. One 
patient suffered from a vasovagal reaction that resolved in 
few minutes after the administration of 1 mg intravenous 
atropine; another patient had a hypertensive crisis which 
subsided without any intervention, but required the 
procedure to be paused for few minutes.
In the last case, an episode of hemoptysis was observed 
immediately after the end of the procedure. Urgent 
bronchoscopy didn’t report iatrogenic lesion and revealed only 
a microscopic clot on the membranous pars of the trachea. 
Hemoptysis was therefore attributed to a mild thermal 
injury of the trachea. No other episodes of hemoptysis were 
registered until the discharge and during follow-up. 
Among the side effects, in the group B we observed one 
case of low-grade fever (<38 ℃) the day after the procedure 
in the context of a mild post-ablation syndrome, which 
resolved within 24 hours. Comparing both major and 
minor complications between the two groups, no significant 
difference was observed in the complication rate (18.2% vs. 
23.1%, respectively; P=0.5049).
Table 8 Summary and comparison of data between the two groups
Groups Reduction volume at 1 month (%) US visibility (mean) Complication rate (%) Symptom score* Cosmetic score*
Group A 36.9 2.8 18.2 3.1–1.4 3.7–3.4
Group B 39.5 3.3 23.1 4–1.6 3.9–3.6
P value 0.3137 0.1448 0.769 0.3305 0.96
*, at baseline and at 1 month.
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Figure 7 Nodule volumetric reduction at 1 month: the two linear 
regression lines do not have significant differences in their slope, 
but group B shows slight better volumetric reduction.
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Table 10 Pain management and adverse events in group B 
Patient
Anesthesiological 
support
Subcapsular 
anesthesia
Major 
complications
Minor complications
Total 
complications (n)
1 Yes No − – –
2 Yes No − Pain → vagal crysys 1
3 No No − Pain → hypertensive crisis 1
4 Yes No − − −
5 No No − − −
6 Yes No − − −
7 Yes No − Hemoptysis 1
8 Yes No − − −
9 Yes Yes − − −
10 No Yes − − −
11 No Yes − − −
12 No Yes − − −
13 No Yes − − −
Total/mean − − 0% 23.1% 3 (23.1%)
Conclusions
Single thyroid nodules or nodular goiter are two common 
clinical conditions, for which surgery has been the traditional 
treatment procedure (21). However, US-guided minimally 
invasive techniques have been developed in the last two 
decades for patients not suitable for thyroidectomy; these 
procedures carry on some advantages, like the absence of 
general anesthesia and scar formation, or the possibility of 
causing iatrogenic hypothyroidism. Furthermore, minimally 
invasive techniques are less costly respect to surgery (22).
Among these, PEI was the first treatment described in 
literature (4), and its indications are mainly related to cystic 
nodules. LA has shown good but slightly worse results, when 
Table 9 Pain management and adverse events in group A
Patient
Anesthesiological 
support
Subcapsular 
anesthesia
Major complications Minor complications
Total 
complications (n)
1 Yes No − − −
2 Yes No − − −
3 Yes No − − −
4 Yes No − − −
5 Yes No − − −
6 Yes No − − −
7 Yes No − − −
8 Yes No − − −
9 Yes No − − −
10 Yes No − Hematoma 1
11 Yes No Laryngeal recurrent nerve palsy − 1
Total/mean − − 9.1% 9.1% 2 (18.2%)
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compared to RFA (5). MWA is an emerging technique (7), 
but the needle’s diameter (14 gauge) represents a major 
limitation when working on the thyroid gland. HIFU (8) is 
a non-invasive procedure recently developed: more studies 
are necessary to evaluate its efficacy.
RFA is currently the most promising alternative to 
surgery in case of benign thyroid nodules. In a recent 
review, 989 benign thyroid nodules in 895 patients divided 
in 16 studies have been encountered (23): mean reduction 
volume after ranged from 50.7% to 93.5%. The Korean 
Society of Thyroid Radiology recently developed a 
consensus to conform RFA treatments (24), in particular 
regarding inclusion criteria and procedural techniques.
Our study represents a single-center experience in the 
treatment with RFA of benign thyroid nodules. To our 
knowledge, no previous studies have described the use and 
compared two different devices. The current series aims to 
evaluate if different needles are associated with differences 
in safety and efficacy of the treatment.
The two devices used were: 
 Amica, HS Hospital Service, Aprilia, Italy (group A);
 Covidien, Mansfield, MA, USA (group B).
They had similar characteristics (both monopolar, 
straight-type, internally cooled needles), but differed for 
needle diameter (18 vs. 17 gauge, respectively) and, in our 
study, US visibility (2.84 in group A vs. 3.29 in group B).
The two groups presented a good matching in patients 
and nodules characteristics, so that a prospective comparative 
evaluation was performed: 
 both groups show female prevalence (5:6 and 
4:9, respectively) and similar mean age (56.9 and 
58.7 years, respectively). Also symptom and cosmetic 
score before the treatment were similar (Tables 5,6);
 In both groups, nodules were mainly part of a goiter; 
composition was mainly solid and vascularization 
mostly intermediate (Tables 1,2). No significant 
difference was observed in the mean volume at 
baseline (Tables 3,4).
Our results confirmed safety and efficacy of percutaneous RFA.
RFA safety profile was confirmed by the presence of only 
one major complication (4.2% prevalence in total, while 
surgery carries a 2–10% complication rate) (3). 
Effectiveness can be only partly confirmed because of 
our short follow-up: data reported in literature demonstrate 
how 1-month follow-up is a too short amount of time to 
evaluate the real reduction of the nodule treated (25,26); 
however, our mean volume reduction (38.3%) is in line 
with other results at 1 month follow-up visits in published 
literature (32.7–46.5%).
A good US visibility of the needle represents an important 
technical aspect that leads to a better working-condition for 
the operator and a safer procedure for the patient.
No significant differences in US visibility was observed 
(P=0.0787), between the two needles, even if the 17 gauge 
needle showed a slight better visibility for the operator 
(3.29 vs. 2.84). Even in terms of volume reduction and 
complication rates the two groups did not report any 
statistically significant difference (Table 8).  
According to these data, our study confirms the efficacy 
of RFA in the treatment of benign thyroid nodules. No 
differences were registered between the uses of the two 
different systems.
In our opinion, a slightly thicker needle may reduce 
the complications due to the incorrect visualization of 
the tip during the procedure (damage to surrounding 
structures), without increasing of the complications related 
to the deployment of the device (mainly bleeding); in 
our experience, the only hematoma observed has been 
developed in one group A patient.
Our study has several limitations, the main ones being 
the little population enrolled and the short follow-up. 
Moreover, our series represent a retrospective observational 
experience. More patients and a longer follow-up are 
necessary to confirm our preliminary results.
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